Scarica l'app Stockscreener
3.24
3.51%
0.11
Dopo l'orario di chiusura:
3.23
-0.01
-0.31%
Precedente Chiudi:
$3.13
Aprire:
$3.2195
Volume 24 ore:
33,781
Relative Volume:
0.02
Capitalizzazione di mercato:
$10.45M
Reddito:
$12.99M
Utile/perdita netta:
$-23.72M
Rapporto P/E:
-0.0333
EPS:
-97.2514
Flusso di cassa netto:
$-23.28M
1 W Prestazione:
+6.93%
1M Prestazione:
-0.31%
6M Prestazione:
-96.49%
1 anno Prestazione:
-98.95%
Intervallo 1D:
$3.20
$3.28
Intervallo di 1 settimana:
$2.93
$3.28
Portata 52W:
$2.81
$381.10
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Nome
Aptevo Therapeutics Inc
Settore
Industria
Telefono
206-838-0500
Indirizzo
2401 4TH AVE., SEATTLE, WA
Confronta APVO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
3.24 | 10.09M | 12.99M | -23.72M | -23.28M | -97.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2018-11-05 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-10-05 | Ripresa | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Borsa (APVO) Ultime notizie
What analysts say about Aptevo Therapeutics Inc. stockDynamic profit opportunities - Autocar Professional
Aptevo Therapeutics Inc. Stock Analysis and ForecastRecord-setting profit potential - Autocar Professional
Is Aptevo Therapeutics Inc. a good long term investmentExceptional market positioning - Autocar Professional
What drives Aptevo Therapeutics Inc. stock priceMarket-beating performance - jammulinksnews.com
Aptevo Meets Nasdaq $2.5M Equity Requirement - MSN
What makes Aptevo Therapeutics Inc. stock price move sharplyFree Access to Community - Newser
Why Aptevo Therapeutics Inc. stock attracts strong analyst attentionFree Elite Traders Group - Newser
How Aptevo Therapeutics Inc. stock performs during market volatility2x 3x 5x Pick Alert - Newser
10 Best Get Rich Quick Stocks to Buy Now - Insider Monkey
Aptevo regains Nasdaq compliance following $15.9 million equity raise By Investing.com - Investing.com India
Aptevo Therapeutics Regains Nasdaq Compliance with Equity Raise - TipRanks
Aptevo regains Nasdaq compliance following $15.9 million equity raise - Investing.com
Aptevo Therapeutics Raises $15.9M to Meet Nasdaq Compliance - TipRanks
Aptevo Therapeutics' Mysterious 10% Spike: What’s Behind the Surge? - AInvest
Aptevo (APVO) appoints Baker Tilly as auditor after Moss Adams merger - Stock Titan
Aptevo Therapeutics Plummets 18%: A Technical & Order-Flow Deep Dive - AInvest
Benzinga Bulls And Bears: Circle, Sunrun, JetBlue — And Mideast Has Markets Nervous - Benzinga
Top Medical Stocks To Watch Today – June 18th - Defense World
Aptevo Therapeutics Surges 82% Amid No Fundamental News—What’s Driving the Spike? - AInvest
Top Small Cap Stocks Worth WatchingJune 18th - MarketBeat
Crude Oil Moves Higher; US Weekly Jobless Claims Decline - Benzinga
Aptevo Therapeutics raises $8 million in registered direct offering - Investing.com Australia
Dow Surges 150 Points; Korn Ferry Earnings Top Views - Benzinga
Aptevo Therapeutics (APVO) Secures $8M Through Direct Offering - GuruFocus
Aptevo Therapeutics announces $8M at-the-market equity offering with warrants; shares more than double - MSN
Aptevo Therapeutics raises $8 million in registered direct offering By Investing.com - Investing.com India
Why Is Micro-Cap Aptevo Stock Trading Higher On Wednesday?Aptevo Therapeutics (NASDAQ:APVO) - Benzinga
Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules | APVO Stock News - GuruFocus
An early stage 85% remissions rate in AML drives Aptevo’s stock surge - BioWorld MedTech
Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules - ACCESS Newswire
Aptevo Secures $8M Funding: Biotech Company Accelerates Cancer Drug Development Pipeline - Stock Titan
Aptevo Therapeutics stock soars after impressive AML treatment results - Investing.com
Aptevo Therapeutics stock soars after impressive AML treatment results By Investing.com - Investing.com Canada
Why did Aptevo Therapeutics Shares Skyrocket in Premarket Trading Today? - Tokenist
Aptevo Therapeutics Skyrockets on Game-Changing AML Drug News - RagingBull
Aptevo reports 85% remission rate in frontline AML trial By Investing.com - Investing.com Nigeria
Aptevo Therapeutics (APVO) Shows Promising Results in RAINIER Tr - GuruFocus
Aptevo Says Its Mipletamig Therapy Achieves 85% Remission Rate in Leukemia Patients; Shares Soar Pre-Bell - MarketScreener
Aptevo Therapeutics (APVO) Shows Promising Results in AML Trial - GuruFocus
Aptevo Therapeutics Inc Azioni (APVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):